Myriad Genetics, Inc.  

(Public, NASDAQ:MYGN)   Watch this stock  
Find more results for Louise Gardner�
+0.97 (2.74%)
Aug 28 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 35.26 - 36.46
52 week 30.30 - 39.95
Open 35.26
Vol / Avg. 1.23M/616,671.00
Mkt cap 2.43B
P/E 33.56
Div/yield     -
EPS 1.09
Shares 68.60M
Beta 0.48
Inst. own 139%
Nov 2, 2015
Q1 2016 Myriad Genetics Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Aug 11, 2015
Q4 2015 Myriad Genetics Inc Earnings Call - Webcast
Aug 11, 2015
Q4 2015 Myriad Genetics Inc Earnings Release
Jun 9, 2015
Myriad Genetics Inc at Goldman Sachs Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2015
Net profit margin 9.85% 11.09%
Operating margin 19.06% 18.56%
EBITD margin - 22.02%
Return on average assets 9.71% 10.09%
Return on average equity 11.28% 11.61%
Employees 2,038 -
CDP Score - -


320 S Wakara Way
SALT LAKE CITY, UT 84108-1214
United States - Map
+1-302-6587581 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is focused on developing and marketing predictive medicine, personalized medicine and prognostic medicine tests. It performs all of its molecular diagnostic testing and analysis in its own reference laboratories. These technologies include the cornerstone technologies of biomarker discovery, high-throughput deoxyribo nucleuc acid (DNA) sequencing, ribo nucleic acid (RNA) expression and multiplex protein analysis. The Company uses this information to guide the development of new molecular diagnostic tests that are designed to assess an individual's risk for developing disease later in life (predictive medicine), identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to ensure optimal treatment (personalized medicine), or assess a patient's risk of disease progression and disease recurrence (prognostic medicine).

Officers and directors

John T. Henderson M.D. Independent Chairman of the Board
Age: 70
Bio & Compensation  - Reuters
Mark C. Capone President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Walter M. Gilbert Ph.D. Independent Vice Chairman of the Board
Age: 82
Bio & Compensation  - Reuters
Richard M. Marsh Esq. Executive Vice President, General Counsel, Secretary
Age: 56
Bio & Compensation  - Reuters
Jayne B. Hart Executive Vice President - Human Resources
Age: 54
Bio & Compensation  - Reuters
Gary A. King Executive Vice President - International Operations
Age: 58
Bio & Compensation  - Reuters
Ronald S. Rogers Executive Vice President - Corporate Communications
Age: 46
Bio & Compensation  - Reuters
Robert Gardner Harrison Chief Information Officer
Age: 48
Bio & Compensation  - Reuters
Jerry S. Lanchbury Ph.D. Chief Scientific Officer
Age: 55
Bio & Compensation  - Reuters
R. Bryan Riggsbee Chief Financial Officer, Executive Vice President, Treasurer
Age: 44
Bio & Compensation  - Reuters